Antagonists of the human A2A receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides

被引:25
作者
Gillespie, Roger J. [2 ]
Bamford, Samantha J. [2 ]
Gaur, Suneel [2 ]
Jordan, Allan M. [1 ]
Lerpiniere, Joanne [2 ]
Mansell, Howard L. [2 ]
Stratton, Gemma C. [2 ]
机构
[1] Vernalis R D Ltd, Cambridge CB21 6GB, England
[2] Vernalis R D Ltd, Winnersh Wokingham RG41 5UA, England
关键词
Adenosine receptor; Parkinson's disease; Pyrimidine; Carboxamide; PARKINSONS-DISEASE; L-DOPA; ADENOSINE; DESIGN; DERIVATIVES; DYSKINESIA; AGONISTS; KW-6002; MONKEYS; POTENT;
D O I
10.1016/j.bmcl.2009.03.142
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of antagonists of the human A(2A) receptor have been identified and have been shown to display good potency and high degrees of selectivity over other receptor sub-types. Displaying in vivo potency in commonly used disease models and high oral bio-availability, this class of compounds may serve as clinically useful treatments for the relief of the symptoms associated with Parkinson's disease. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2664 / 2667
页数:4
相关论文
共 27 条
[1]   7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists:: A study on the importance of modifications at the side chain on the activity and solubility [J].
Baraldi, PG ;
Cacciari, B ;
Romagnoli, R ;
Spalluto, G ;
Monopoli, A ;
Ongini, E ;
Varani, K ;
Borea, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) :115-126
[2]   Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A(2A) adenosine antagonists [J].
Baraldi, PG ;
Cacciari, B ;
Spalluto, G ;
Villatoro, MJPDIY ;
Zocchi, C ;
Dionisotti, S ;
Ongini, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (05) :1164-1171
[3]  
Bezard E, 1998, REV NEUROSCIENCE, V9, P71
[4]  
CAULKETT PWR, 1995, J CHEM SOC P1, V7, P801
[5]   Adenosine A(2A) receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats [J].
Fenu, S ;
Pinna, A ;
Ongini, E ;
Morelli, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (02) :143-147
[6]   Entry into a new class of protein kinase inhibitors by pseudo ring design [J].
Furet, Pascal ;
Caravatti, Giorgio ;
Guagnano, Vito ;
Lang, Marc ;
Meyer, Thomas ;
Schoepfer, Joseph .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) :897-900
[7]  
GILLESPIE R, 2005, Patent No. 2005079801
[8]   Antagonists of the human adenosine A2A receptor.: Part 3:: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d] pyrimidines and 6-arylpurines [J].
Gillespie, Roger J. ;
Cliffe, Ian A. ;
Dawson, Claire E. ;
Dourish, Colin T. ;
Gaur, Suneel ;
Jordan, Allan M. ;
Knight, Antony R. ;
Lerpiniere, Joanne ;
Misra, Anil ;
Pratt, Robert M. ;
Roffey, Jonathan ;
Stratton, Gemma C. ;
Upton, Rebecca ;
Weiss, Scott M. ;
Williamson, Douglas S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (09) :2924-2929
[9]   Antagonists of the human adenosine A2A receptor.: Part 1:: Discovery and synthesis of thieno[3,2-d] pyrimidine-4-methanone derivatives [J].
Gillespie, Roger J. ;
Adams, David R. ;
Bebbington, David ;
Benwell, Karen ;
Cliffe, Ian A. ;
Dawson, Claire E. ;
Dourish, Colin T. ;
Fletcher, Allan ;
Gaur, Suneel ;
Giles, Paul R. ;
Jordan, Allan M. ;
Knight, Antony R. ;
Knutsen, Lars J. S. ;
Lawrence, Anthony ;
Lerpiniere, Joanne ;
Misra, Anil ;
Porter, Richard H. P. ;
Pratt, Robert M. ;
Shepherd, Robin ;
Upton, Rebecca ;
Ward, Simon E. ;
Weiss, Scott M. ;
Williamson, Douglas S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (09) :2916-2919
[10]   Antagonists of the human adenosine A2A receptor.: Part 2:: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives [J].
Gillespie, Roger J. ;
Cliffe, Ian A. ;
Dawson, Claire E. ;
Dourish, Colin T. ;
Gaur, Suneel ;
Giles, Paul R. ;
Jordan, Allan M. ;
Knight, Antony R. ;
Lawrence, Anthony ;
Lerpiniere, Joanne ;
Misra, Anil ;
Pratt, Robert M. ;
Todd, Richard S. ;
Upton, Rebecca ;
Weiss, Scott M. ;
Williamson, Douglas S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (09) :2920-2923